CD52 as both a marker and an effector molecule of T cells with regulatory action: Identification of novel regulatory T cells

Cellular and Molecular Immunology

Volumn 10, Issue 6, 2013, Pages 456-458

  Samten, Buka ^a  

^a UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD52 ANTIGEN; CYTOKINE; GAMMA INTERFERON; GLUTAMATE DECARBOXYLASE 65; INTERLEUKIN 2 RECEPTOR ALPHA; PHOSPHOLIPASE C; SIALIC ACID BINDING IMMUNOGLOBULIN LIKE LECTIN; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR FOXP3;

ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; AUTOIMMUNE DISEASE; CD4+ T LYMPHOCYTE; CYTOKINE PRODUCTION; DIABETES MELLITUS; HUMAN; IMMUNOREGULATION; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; NONHUMAN; NOTE; PERIPHERAL BLOOD MONONUCLEAR CELL; REGULATORY T LYMPHOCYTE;

ANIMALS; ANTIGENS, CD; ANTIGENS, NEOPLASM; CD4-POSITIVE T-LYMPHOCYTES; DIABETES MELLITUS, TYPE 1; FEMALE; GLYCOPROTEINS; HUMANS; LYMPHOCYTE ACTIVATION; MALE; SIALIC ACID BINDING IMMUNOGLOBULIN-LIKE LECTINS;

EID: 84888382298     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2013.38     Document Type: Note

References (12)

1. 1 Tregs and immune control. J Clin Invest 2004; 114: 1209-1217.
2. Pillai V, Karandikar NJ. Human regulatory T cells: a unique, stable thymic subset or a reversible peripheral state of differentiation? Immunol Lett 2007; 114: 9-15. (Pubitemid 47625594)
3. Shevach EM. From vanilla to 28 flavors: multiple varieties of T regulatory cells. Immunity 2006; 25: 195-201. (Pubitemid 44224153)
4. Bandala-Sanchez E, Zhang YX, Reinwald S, Dromey JS, Lee B, Qian JY et al. T cell regulation mediated by interaction of soluble CD52 with the inhibitory receptor Siglec-10. Nat Immunol 2013; 14: 741-748.
5. 1 T-cell clones specific for pancreatic islet autoantigens. J Autoimmun 2011; 36: 47-55.
6. Albitar M, Do KA, Johnson MM, Giles FJ, Jilani I, O'Brien S et al. Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies. Cancer 2004; 101: 999-1008. (Pubitemid 39100434)
7. Xia MQ, Hale G, Lifely MR, Ferguson MA, Campell D, Packman L et al. Structure of the CAMPATH-1 antigen, a glycosyl-phosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis. Biochem J 1993; 293(Pt 3): 633-640. (Pubitemid 23244542)
8. Treumann A, Lifely MR, Schneider P, Ferguson MA. Primary structure of CD52. J Biol Chem 1995; 270: 6088-6099.
9. 1 regulatory T cells. Clinl immunol 2006; 120: 247-259. (Pubitemid 44175899)
10. Tang Q, Henriksen KJ, Bi M, Finger EB, Szot G, Ye J et al. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med 2004; 199: 1455-1465. (Pubitemid 38780401)
11. 1 regulatory T cells in pancreatic lymph nodes in diabetic NOD mice by adjuvant immunotherapy. Transplantation 2009; 87: 198-206.
12. 1 T cells from glutamic acid decarboxylase (GAD)65-specific T cell receptor transgenic mice are not diabetogenic and can delay diabetes transfer. J Exp Med 2002; 196: 481-492.